{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:23:48Z","timestamp":1791318228232,"version":"4.3.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2017,12]]},"abstract":"\n Targeted delivery of a therapeutic agent to a site of pathology to ameliorate disease while limiting exposure at undesired tissues is an aspirational treatment scenario. Targeting diseased kidneys for pharmacologic treatment has had limited success. We designed an approach to target an extracellular matrix protein, the fibronectin extra domain A isoform (FnEDA), which is relatively restricted in distribution to sites of tissue injury. In a mouse unilateral ureteral obstruction (UUO) model of renal fibrosis, injury induced significant upregulation of FnEDA in the obstructed kidney. Using dual variable domain Ig (DVD-Ig) technology, we constructed a molecule with a moiety to target FnEDA and a second moiety to neutralize TGF-\n \u03b2<\/jats:italic>\n . After systemic injection of the bispecific TGF-\n \u03b2<\/jats:italic>\n + FnEDA DVD-Ig or an FnEDA mAb, chemiluminescent detection and imaging with whole-body single-photon emission computed tomography (SPECT) revealed significantly higher levels of each molecule in the obstructed kidney than in the nonobstructed kidney, the ipsilateral kidney of sham animals, and other tissues. In comparison, a systemically administered TGF-\n \u03b2<\/jats:italic>\n mAb accumulated at lower concentrations in the obstructed kidney and exhibited a more diffuse whole-body distribution. Systemic administration of the bispecific DVD-Ig or the TGF-\n \u03b2<\/jats:italic>\n mAb (1\u201310 mg\/kg) but not the FnEDA mAb attenuated the injury-induced collagen deposition detected by immunohistochemistry and elevation in Col1a1, FnEDA, and TIMP1 mRNA expression in the obstructed kidney. Overall, systemic delivery of a bispecific molecule targeting an extracellular matrix protein and delivering a TGF-\n \u03b2<\/jats:italic>\n mAb resulted in a relatively focal uptake in the fibrotic kidney and reduced renal fibrosis.\n <\/jats:p>","DOI":"10.1681\/asn.2017010013","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T20:20:13Z","timestamp":1503346813000},"page":"3616-3626","source":"Crossref","is-referenced-by-count":52,"title":["Targeting Anti\u2013TGF-\u03b2 Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach"],"prefix":"10.1681","volume":"28","author":[{"given":"Steve","family":"McGaraughty","sequence":"first","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Davis-Taber","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Z.","family":"Zhu","sequence":"additional","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd B.","family":"Cole","sequence":"additional","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur L.","family":"Nikkel","sequence":"additional","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Chhaya","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Doyle","sequence":"additional","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Olson","sequence":"additional","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Preston","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Grinnell","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Salte","sequence":"additional","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Giamis","sequence":"additional","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Luo","sequence":"additional","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sun","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Goodearl","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Gopalakrishnan","sequence":"additional","affiliation":[{"name":"AbbVie Discovery Lake County, North Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Lacy","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"B1-20230819","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1517\/17425247.2015.1071352","article-title":"\u2018Smart\u2019 nanoparticles as drug delivery systems for applications in tumor therapy.","volume":"12","author":"Fang","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"B2-20230819","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acs.bioconjchem.5b00291","article-title":"Aptamer-drug conjugates.","volume":"26","author":"Zhu","year":"2015","journal-title":"Bioconjug Chem"},{"key":"B3-20230819","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrrheum.2015.17","article-title":"Trojan horses and guided missiles: Targeted therapies in the war on arthritis.","volume":"11","author":"Ferrari","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B4-20230819","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.addr.2010.10.002","article-title":"Targeted renal therapies through microbubbles and ultrasound.","volume":"62","author":"Deelman","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"B5-20230819","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1208\/s12249-015-0350-9","article-title":"Colon-targeted oral drug delivery systems: Design trends and approaches.","volume":"16","author":"Amidon","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"B6-20230819","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1053\/j.ackd.2013.06.003","article-title":"Targeting therapeutics to the glomerulus with nanoparticles.","volume":"20","author":"Zuckerman","year":"2013","journal-title":"Adv Chronic Kidney Dis"},{"key":"B7-20230819","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.addr.2010.07.011","article-title":"Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells.","volume":"62","author":"Dolman","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"B8-20230819","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.addr.2010.08.011","article-title":"Mesangial pathology in glomerular disease: Targets for therapeutic intervention.","volume":"62","author":"Scindia","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"B9-20230819","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.addr.2010.08.012","article-title":"Targeting podocyte-associated diseases.","volume":"62","author":"Leeuwis","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"B10-20230819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.2388","article-title":"New insights into form and function of fibronectin splice variants.","volume":"216","author":"White","year":"2008","journal-title":"J Pathol"},{"key":"B11-20230819","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/iub.493","article-title":"Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models.","volume":"63","author":"White","year":"2011","journal-title":"IUBMB Life"},{"key":"B12-20230819","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH783>3.0.CO;2-P","article-title":"Distribution of fibronectin isoforms in human renal disease.","volume":"193","author":"Van Vliet","year":"2001","journal-title":"J Pathol"},{"key":"B13-20230819","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.1653","article-title":"Alternatively spliced isoforms of fibronectin in immune-mediated glomerulosclerosis: The role of TGFbeta and IL-4.","volume":"204","author":"Baelde","year":"2004","journal-title":"J Pathol"},{"key":"B14-20230819","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/MIB.0000000000000440","article-title":"Alternatively spliced EDA domain of fibronectin is a target for pharmacodelivery applications in inflammatory bowel disease.","volume":"21","author":"Bootz","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"B15-20230819","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nbt0315-219","article-title":"Amgen\u2019s bispecific antibody puffs across finish line.","volume":"33","author":"Sheridan","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B16-20230819","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4161\/mabs.23977","article-title":"Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig\u2122) molecule.","volume":"5","author":"Jakob","year":"2013","journal-title":"MAbs"},{"key":"B17-20230819","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/jcph.764","article-title":"Pharmacokinetics and tolerability of a dual variable domain immunoglobulin ABT-981 against IL-1\u03b1 and IL-1\u03b2 in healthy subjects and patients with osteoarthritis of the knee.","volume":"56","author":"Kosloski","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"B18-20230819","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","article-title":"Transforming growth factor beta in tissue fibrosis.","volume":"331","author":"Border","year":"1994","journal-title":"N Engl J Med"},{"key":"B19-20230819","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fphys.2015.00082","article-title":"TGF-\u03b2\/Smad signaling in renal fibrosis.","volume":"6","author":"Meng","year":"2015","journal-title":"Front Physiol"},{"key":"B20-20230819","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/ki.1993.312","article-title":"Interstitial fibrosis in obstructive nephropathy.","volume":"44","author":"Sharma","year":"1993","journal-title":"Kidney Int"},{"key":"B21-20230819","first-page":"528","article-title":"Chronic unilateral ureteral obstruction is associated with interstitial fibrosis and tubular expression of transforming growth factor-beta.","volume":"74","author":"Wright","year":"1996","journal-title":"Lab Invest"},{"key":"B22-20230819","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.4049\/jimmunol.142.5.1536","article-title":"Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification.","volume":"142","author":"Dasch","year":"1989","journal-title":"J Immunol"},{"key":"B23-20230819","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI31487","article-title":"Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.","volume":"117","author":"Wynn","year":"2007","journal-title":"J Clin Invest"},{"key":"B24-20230819","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/ki.1996.65","article-title":"Expression of transforming growth factor-beta isoforms in human glomerular diseases.","volume":"49","author":"Yamamoto","year":"1996","journal-title":"Kidney Int"},{"key":"B25-20230819","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1097\/01.ASN.0000033611.79556.AE","article-title":"TGF-beta signaling in renal disease.","volume":"13","author":"B\u00f6ttinger","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B26-20230819","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/ki.1993.246","article-title":"Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation.","volume":"44","author":"Kaneto","year":"1993","journal-title":"Kidney Int"},{"key":"B27-20230819","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0024-3205(98)00166-0","article-title":"Transforming growth factor-beta receptor types I and II are expressed in renal tubules and are increased after chronic unilateral ureteral obstruction.","volume":"62","author":"Sutaria","year":"1998","journal-title":"Life Sci"},{"key":"B28-20230819","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ki.2011.33","article-title":"A phase 1, single-dose study of fresolimumab, an anti-TGF-\u03b2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis.","volume":"79","author":"Trachtman","year":"2011","journal-title":"Kidney Int"},{"key":"B29-20230819","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1046\/j.1523-1755.2000.00414.x","article-title":"Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction.","volume":"58","author":"Miyajima","year":"2000","journal-title":"Kidney Int"},{"key":"B30-20230819","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2337\/diab.45.4.522","article-title":"Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.","volume":"45","author":"Sharma","year":"1996","journal-title":"Diabetes"},{"key":"B32-20230819","doi-asserted-by":"crossref","first-page":"964","DOI":"10.7150\/ijbs.4564","article-title":"Complexities of TGF-\u03b2 targeted cancer therapy.","volume":"8","author":"Connolly","year":"2012","journal-title":"Int J Biol Sci"},{"key":"B33-20230819","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/359693a0","article-title":"Targeted disruption of the mouse transforming growth factor-\u03b2 1 gene results in multifocal inflammatory disease.","volume":"359","author":"Shull","year":"1992","journal-title":"Nature"},{"key":"B34-20230819","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.trsl.2014.07.010","article-title":"Therapeutic targets for treating fibrotic kidney diseases.","volume":"165","author":"Lee","year":"2015","journal-title":"Transl Res"},{"key":"B35-20230819","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-015-1653-0","article-title":"Cutaneous keratoacanthomas\/squamous cell carcinomas associated with neutralization of transforming growth factor \u03b2 by the monoclonal antibody fresolimumab (GC1008).","volume":"64","author":"Lacouture","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B36-20230819","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/VHRM.S1991","article-title":"Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers.","volume":"4","author":"Ban","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"B37-20230819","first-page":"296","article-title":"[The role of transforming growth factor-beta in the pathogenesis of diabetic retinopathy]","volume":"63","author":"Gacka","year":"2006","journal-title":"Przegl Lek"},{"key":"B38-20230819","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/febs.13665","article-title":"TGF-\u03b2 signalling and liver disease.","volume":"283","author":"Fabregat","year":"2016","journal-title":"FEBS J"},{"key":"B39-20230819","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbadis.2009.06.004","article-title":"TGF-beta and fibrosis in different organs - molecular pathway imprints.","volume":"1792","author":"Pohlers","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"B40-20230819","first-page":"913","article-title":"Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta.","volume":"86","author":"Lee","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B41-20230819","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/cyto.1995.0054","article-title":"Characterization of recombinant soluble human transforming growth factor-beta receptor type II (rhTGF-beta sRII).","volume":"7","author":"Tsang","year":"1995","journal-title":"Cytokine"},{"key":"B42-20230819","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models.","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol Ind Health"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201712000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:29:34Z","timestamp":1786130974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201712000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2017010013","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]}}}